Clinical Trial

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Protocol Amendment History 1 change
notable Trial sites expanded: 6 -> 15 locations 2026-07-07
Trial Details
NCT Number NCT07226427
Lead Sponsor Stemline Therapeutics, Inc.
Conditions Platinum-resistant Ovarian Cancer
Enrollment 100 participants
Start Date 2026-01-10
Primary Completion 2027-12-02 (estimated)
Study Completion 2028-06-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-06